We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+13.44%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$329M
AUM Growth
+$94M
Cap. Flow
+$80.7M
Cap. Flow %
24.51%
Top 10 Hldgs %
27.28%
Holding
112
New
38
Increased
35
Reduced
8
Closed
25

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$7.49M
2
KTWO
K2M Group Holdings, Inc
KTWO
+$6.3M
3
SYK icon
Stryker
SYK
+$5.17M
4
MEDP icon
Medpace
MEDP
+$4.63M
5
ABT icon
Abbott
ABT
+$4.5M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$6.94M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.34M
3
UHS icon
Universal Health Services
UHS
+$5.36M
4
MCK icon
McKesson
MCK
+$5.13M
5
ACH
Accendra Health
ACH
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 62.31%
2 Financials 2.43%
3 Industrials 2.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSII
101
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-145,289
Closed -$2.67M
IVC
102
CALL
DELISTED
Invacare Corporation
IVC
– –
-125,000
Closed -$1.52M
XENT
103
CALL
DELISTED
Intersect ENT, Inc
XENT
– –
-100,000
Closed -$1.29M
ALXN
104
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-37,500
Closed -$4.38M
GWPH
105
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-18,000
Closed -$1.65M
VAR
106
PUT
DELISTED
Varian Medical Systems, Inc.
VAR
– –
-28,510
Closed -$2.06M
ELGX
107
DELISTED
Endologix Inc
ELGX
– –
-20,500
Closed -$2.55M
CPHD
108
DELISTED
Cepheid Inc
CPHD
– –
-95,000
Closed -$2.92M
CYNA
109
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-200,845
Closed -$3.36M
ZGNX
110
DELISTED
Zogenix, Inc.
ZGNX
– –
-58,750
Closed -$473K
CELG
111
DELISTED
Celgene Corp
CELG
– –
-41,875
Closed -$4.13M
MDVN
112
DELISTED
MEDIVATION, INC.
MDVN
– –
-36,250
Closed -$2.19M
1 2 3 4
5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2016 Portfolio in Review

As of Q3 2016, Pura Vida Investments held 112 positions worth $329M, up 40% from $235M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Pura Vida Investments deployed $80.7M of net new capital in Q3 2016, opening 38 new positions and adding to 35 existing holdings. Its largest new stake was Novartis: 102,812 shares worth $7.27M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 63% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Insulet, an estimated $2.8M trimmed.

  • Pura Vida Investments's largest Q3 2016 buy was Novartis: 102,812 shares worth $7.27M.
  • Pura Vida Investments added most to Stryker in Q3 2016, an estimated $5.17M increase.
  • Pura Vida Investments's biggest Q3 2016 reduction was Insulet, cutting an estimated $2.8M.
  • Pura Vida Investments fully exited Medtronic in Q3 2016, selling an estimated $6.94M.
  • Pura Vida Investments's ten largest holdings make up 27% of its $329M portfolio in Q3 2016.
  • Pura Vida Investments opened 38 new positions and closed 25 in Q3 2016.
  • Pura Vida Investments's portfolio value rose 40% quarter-over-quarter to $329M.

Based on Pura Vida Investments's 13F filing for Q3 2016, filed 14 Nov 2016.